Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

• Authors: Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L Perkins, J Kimble Frazer, Warren Sanger, James R Anderson, Thomas G Gross, Howard Weinstein, Lauren Harrison, Matthew J Barth, Lara Mussolin, Mitchell S Cairo
• Journal: British journal of haematology (Br J Haematol) Vol. 170 Issue 3 Pg. 367-71 (Aug 2015) ISSN: 1365-2141 [Electronic] England
• PMID: 25858645 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 John Wiley & Sons Ltd.

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Burkitt Lymphoma (blood, drug therapy)
• Central Nervous System Neoplasms (blood, drug therapy)
• Child
• Child, Preschool
• Consolidation Chemotherapy
• Female
• Humans
• Male
• Neoplasm, Residual
• Pilot Projects
• Real-Time Polymerase Chain Reaction